# RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)

> **NCT03813641** · PHASE2 · UNKNOWN · sponsor: **Shenzhen People's Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Raltitrexed
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT03813641
- **Lead sponsor:** Shenzhen People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-28
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03813641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03813641, "RALOX or CAPOX + Bevacizumab in the First-line Treatment of Advanced CRC(ROCB Study)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03813641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*